Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-in-class NMT Inhibitor, in Non-Hodgkin’s Lymphomas and Solid Tumor Patients

Key Takeaways:

• PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
• Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
• This open label, dose escalation study will examine the safety and tolerability of PCLX-001.